CorMedix (NASDAQ:CRMD) & InMed Pharmaceuticals (NASDAQ:INM) Head-To-Head Survey

InMed Pharmaceuticals (NASDAQ:INM) and CorMedix (NASDAQ:CRMD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Earnings & Valuation

This table compares InMed Pharmaceuticals and CorMedix”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94 million	0.93	-$12.56 million	($1.64)	-0.85
CorMedix	$457.20 million	1.37	$163.05 million	$2.14	3.77

CorMedix has higher revenue and earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

InMed Pharmaceuticals has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for InMed Pharmaceuticals and CorMedix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1	0	0	0	1.00
CorMedix	0	2	7	0	2.78

CorMedix has a consensus price target of $15.00, suggesting a potential upside of 85.99%. Given CorMedix’s stronger consensus rating and higher probable upside, analysts clearly believe CorMedix is more favorable than InMed Pharmaceuticals.

Profitability

This table compares InMed Pharmaceuticals and CorMedix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	N/A	-156.08%	-123.90%
CorMedix	40.49%	40.52%	20.61%

Institutional and Insider Ownership

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of CorMedix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

CorMedix beats InMed Pharmaceuticals on 14 of the 14 factors compared between the two stocks.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.